Heuron Partners with BDMS for Alzheimer’s Research Collaboration

2024-08-23

[보도자료][휴런] 휴런, 태국 최대 헬스케어 그룹 BDMS와 연구협업.jpg


Bangkok, August 1st, 2024 — Heuron, a leading artificial intelligence (AI) healthcare company focused on neurological disorders, has announced a research collaboration with Bangkok Dusit Medical Services (BDMS), Thailand’s largest healthcare group. The partnership, unveiled during a signing ceremony in Bangkok, aims to advance the diagnosis of Alzheimer’s disease through AI technology.


Mr. Chanick Park, Chief Business Officer of Heuron, and Dr. Chotipat Danchaivijitr, Principal Investigator of the research study from Bangkok Hospital, a member of BDMS, attended the ceremony. BDMS operates 58 hospitals across Thailand and Cambodia, including Bangkok Hospital, making it the largest private medical system in the country and one of the top five private hospital operators globally by market capitalization.


The collaboration will involve a two-year study at Bangkok Hospital, utilizing Heuron’s AI solution, Heuron AD, to assist in diagnosing Alzheimer’s disease. The research, titled “Investigation of the Correlation between Brain Atrophy and Alzheimer’s Disease through AI-Based MRI Analysis,” aims to evaluate the efficacy of Heuron AD in distinguishing between normal cognitive function, mild cognitive impairment, and Alzheimer’s disease in Thai patients.


Dr. Danchaivijitr will lead the study from Bangkok Hospital’s Neurology Department and will analyze data from over 100 Thai individuals.


Commenting on the partnership, Dr. Dong-Hoon Shin, CEO of Heuron, expressed optimism about the collaboration. “We are delighted to work with BDMS, Thailand’s largest healthcare network, which has a significant influence in the region. This partnership offers a valuable opportunity to showcase the exceptional performance of Heuron’s AI solution across diverse populations, including both Korean and Thai patients,” said Dr. Shin.